Analysts expect that MEDNAX Inc (NYSE:MD) will report earnings of $0.82 per share for the current quarter, Zacks reports. Eight analysts have made estimates for MEDNAX’s earnings, with the highest EPS estimate coming in at $0.83 and the lowest estimate coming in at $0.80. MEDNAX also reported earnings per share of $0.82 in the same quarter last year. The company is expected to report its next earnings report on Thursday, April 27th.

According to Zacks, analysts expect that MEDNAX will report full year earnings of $4.01 per share for the current fiscal year, with EPS estimates ranging from $3.87 to $4.13. For the next fiscal year, analysts forecast that the company will report earnings of $4.40 per share, with EPS estimates ranging from $4.21 to $4.53. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover MEDNAX.

MEDNAX (NYSE:MD) last issued its earnings results on Tuesday, February 7th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.06. The business had revenue of $831 million for the quarter, compared to analysts’ expectations of $842.15 million. MEDNAX had a return on equity of 13.59% and a net margin of 10.21%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same period last year, the company posted $1.13 earnings per share.

Several research analysts have issued reports on the company. Jefferies Group LLC reaffirmed a “hold” rating and issued a $63.00 price target on shares of MEDNAX in a report on Wednesday, February 8th. They noted that the move was a valuation call. Zacks Investment Research raised MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, March 15th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $69.00 price target on shares of MEDNAX in a report on Friday, March 10th. Finally, Robert W. Baird cut MEDNAX from an “outperform” rating to a “neutral” rating and set a $72.00 price target on the stock. in a report on Tuesday, March 21st. Eight investment analysts have rated the stock with a hold rating, The company presently has an average rating of “Hold” and a consensus target price of $69.00.

COPYRIGHT VIOLATION NOTICE: “$0.82 Earnings Per Share Expected for MEDNAX Inc (MD) This Quarter” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/04/18/0-82-earnings-per-share-expected-for-mednax-inc-md-this-quarter.html.

Shares of MEDNAX (NYSE:MD) traded down 1.24% during trading on Thursday, hitting $67.15. The stock had a trading volume of 544,733 shares. MEDNAX has a one year low of $59.36 and a one year high of $76.96. The firm has a market cap of $6.23 billion, a P/E ratio of 19.24 and a beta of 0.67. The firm’s 50-day moving average is $69.53 and its 200-day moving average is $67.31.

In other news, CFO Vivian Lopez-Blanco sold 15,164 shares of the business’s stock in a transaction on Friday, February 17th. The shares were sold at an average price of $70.01, for a total transaction of $1,061,631.64. Following the transaction, the chief financial officer now directly owns 59,097 shares in the company, valued at approximately $4,137,380.97. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Dominic J. Andreano sold 6,000 shares of the business’s stock in a transaction on Thursday, February 16th. The shares were sold at an average price of $69.59, for a total transaction of $417,540.00. Following the transaction, the senior vice president now owns 30,746 shares in the company, valued at $2,139,614.14. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 86,296 shares of company stock worth $5,959,391. Corporate insiders own 2.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Nordea Investment Management AB boosted its position in MEDNAX by 2.1% in the third quarter. Nordea Investment Management AB now owns 2,878,350 shares of the company’s stock valued at $190,691,000 after buying an additional 60,410 shares in the last quarter. Wells Fargo & Company MN boosted its position in MEDNAX by 3.1% in the third quarter. Wells Fargo & Company MN now owns 652,042 shares of the company’s stock valued at $43,198,000 after buying an additional 19,791 shares in the last quarter. Nikko Asset Management Americas Inc. acquired a new stake in shares of MEDNAX during the third quarter worth about $1,060,000. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of MEDNAX by 1.4% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 260,028 shares of the company’s stock worth $17,227,000 after buying an additional 3,716 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of MEDNAX by 2.0% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,483 shares of the company’s stock worth $893,000 after buying an additional 270 shares in the last quarter. Institutional investors and hedge funds own 99.16% of the company’s stock.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

5 Day Chart for NYSE:MD

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.